Research programme: PIM kinase inhibitors - Senhwa BiosciencesAlternative Names: CX-6258
Latest Information Update: 19 Apr 2016
At a glance
- Originator Cylene Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein-serine-threonine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Leukaemia; Solid tumours